Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease
- 17 July 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1364-1371
Abstract
INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.Keywords
This publication has 28 references indexed in Scilit:
- Epidemiology and Outcomes of Alcohol-Associated Hepatitis in Adolescents and Young AdultsJAMA Network Open, 2024
- Diagnosis and Treatment of Alcohol‐Associated Liver Disease: A Patient‐Friendly Summary of the 2019 AASLD GuidelinesClinical Liver Disease, 2021
- Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver DiseasesHepatology, 2019
- Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitisJournal of Hepatology, 2018
- Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver diseaseJournal of Hepatology, 2017
- Predicting Short-Term Mortality and Long-Term Survival for Hospitalized US Patients with Alcoholic HepatitisDigestive Diseases and Sciences, 2014
- Global burden of alcoholic liver diseasesJournal of Hepatology, 2013
- The model for end-stage liver disease (MELD)Hepatology, 2007
- MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitisJournal of Hepatology, 2005
- Model for end stage liver disease score predicts mortality across a broad spectrum of liver diseaseJournal of Hepatology, 2004